CareDx Sells Lab Products Business for $171.2M

By Philip Seaworth • Wednesday, July 08 13:02 • Permanent Link

CareDx completed the sale of its lab products business to Eurobio Scientific on June 30, 2026, and received $171.2 million in cash at closing, subject to customary post-closing adjustments.

The divested unit included CareDx’s IVD PCR kits for rapid deceased donor HLA typing, IVD NGS-based kits for transplant recipient HLA typing globally, and IVD NGS-based monitoring assays for solid organ and stem cell transplant recipients outside North America.

The sale narrows CareDx’s business toward its U.S. precision medicine testing services and patient and digital solutions. Management said the transaction simplifies the operating model and supports capital allocation, including investments in specialty oncology.

CareDx said it expects to provide more detail on the financial impact of the deal, including pro forma results, when it reports second-quarter 2026 earnings. Today the company's shares have moved -1.94% to a price of $27.76. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.